Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

schistosomiasis - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

schistosomiasis

MONDO:0015254

Also known as:Bilharziabilharziasissnail fever

Find Clinical TrialsTrials

Overview

An infectious disease caused by parasitic trematodes of the genus Schistosoma that colonize human blood vessels and release eggs that can cause granulomatous reactions leading to acute (swimmer's itch or acute schistosomiasis syndrome) or chronic disease. Depending on where the eggs lodge, manifestations of chronic schistosomiasis can include diarrhea, abdominal pain, loss of appetite, anemia (intestines), hepatosplenism, periportal fibrosis with portal hypertension (liver), urogenital inflammation and scarring, hematuria and dysuria (genitourinary system). Other patients may be asymptomatic.

Treatments1 FDA approved

Clinical Trials13 registered · 5 recruiting

Diagnosis

Biomarker and diagnostic research for schistosomiasis has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for schistosomiasis, including PRAZIQUANTEL (BILTRICIDE, approved 1982). An additional 2 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Prognosis

Estimated prevalence: <1 in 1,000,000 (VERY_RARE).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

13 clinical trials registered, 5 recruiting. Interventions under study include other interventions, drug therapy, medical devices, and procedural interventions. Pipeline includes 1 PHASE2, 6 NA. Research is primarily sponsored by academic and government institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT07358910](https://clinicaltrials.gov/study/NCT07358910)

Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 12:58 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:1247

GARD

Genetic and Rare Diseases Info Center

GARD:9687

Questions for Your Care Team

→What are the benefits and potential side effects of BILTRICIDE for managing schistosomiasis?
→Are any of the 13 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
Aggregated polymer of protein magnesium ammonium phospholinoleate-palmitoleate anhydride	Aggregated polymer of protein magnesium ammonium phospholinoleate-palmitoleate anhydride	Farmabrasilis	2020	—	Designated
miltefosine	miltefosine	Profounda, Inc.	2017	—	Designated

Research Type	Count	% of Total
Disease patterns and progression	87	40%
Research summaries	57	26%
Laboratory research	29	13%
Patient case studies	19	9%
Testing and diagnosis research	10	5%
Clinical study results	6	3%
New treatment approaches	5	2%
Other research	3	1%

Kisho

schistosomiasis

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Testicular Schistosomiasis Mimicking Testicular Tumour: A Case Report.

Population genomics reveals multi-scale mechanisms sustaining schistosomiasis re-emergence in a near-elimination setting.

Local cytokine modulation and parasite visceralization during murine coinfection with Leishmania amazonensis and Schistosoma mansoni.

schistosomiasis

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Testicular Schistosomiasis Mimicking Testicular Tumour: A Case Report.

Population genomics reveals multi-scale mechanisms sustaining schistosomiasis re-emergence in a near-elimination setting.

Local cytokine modulation and parasite visceralization during murine coinfection with Leishmania amazonensis and Schistosoma mansoni.